Advertisement Optimer to secure $12.2 million in financing - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Optimer to secure $12.2 million in financing

Optimer Pharmaceuticals has received commitments from selected investors to purchase an aggregate of 1.44 million shares of Optimer's common stock at a purchase price of $8.48 per share pursuant to an effective shelf registration statement.

The closing of this offering is expected to take place on July 25, 2008.
Proceeds from the transaction will be used in the further development of Optimer’s ongoing programs, as well as for other general corporate purposes.